Janux Therapeutics Shares Soar Following Prostate Cancer Treatment Results

By MarketWatch | Dec 2, 2024 at 06:29 PM EST

Janux Therapeutics saw a significant increase in stock value as its prostate cancer treatment, JANX007, showed promising results in a Phase 1a trial. The drug will now undergo expansion trials for patients who haven't used existing therapies, potentially addressing an unmet medical need.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.